Brekke, Kurt R.; Grasdal, Astrid L.; Holmås, Tor Helge

Working Paper

Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation?

CESifo Working Paper, No. 2059

Provided in Cooperation with:
Ifo Institute – Leibniz Institute for Economic Research at the University of Munich

Suggested Citation: Brekke, Kurt R.; Grasdal, Astrid L.; Holmås, Tor Helge (2007) : Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation?, CESifo Working Paper, No. 2059, Center for Economic Studies and Ifo Institute (CESifo), Munich

This Version is available at:
http://hdl.handle.net/10419/26104

Terms of use:
Documents in EconStor may be saved and copied for your personal and scholarly purposes.

You are not to copy documents for public or commercial purposes, to exhibit the documents publicly, to make them publicly available on the internet, or to distribute or otherwise use the documents in public.

If the documents have been made available under an Open Content Licence (especially Creative Commons Licences), you may exercise further usage rights as specified in the indicated licence.

www.econstor.eu
REGULATION AND PRICING OF PHARMACEUTICALS: REFERENCE PRICING OR PRICE CAP REGULATION?

Abstract

We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” for a sub-sample of off-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel dataset, covering the drugs exposed to RP and a large number of drugs still under PC regulation in the time before and after the policy change. Our results show that RP significantly reduces both brand-name and generic prices within the reference group, with the effect being stronger for brand-names. We also identify a negative cross-price effect on therapeutic substitutes not included in the RP-system. In terms of policy implications, the results suggest that RP is more effective than PC regulation in lowering drug prices, while the cross-price effect raises a concern about patent protection.


Keywords: pharmaceuticals, price regulation, branded-generic competition.

Kurt R. Brekke
Norwegian School of Economics and Business Administration
Department of Economics
Helleveien 30
Norway - 5045 Bergen
kurt.brekke@nhh.no

Astrid L. Grasdal
University of Bergen
Department of Economics
Herman Fossgrt. 6
5007 Bergen
Norway
astrid.grasdal@econ.uib.no

Tor Helge Holmås
Institute for Research in Economics and Business Administration
Health Economic Bergen
Norway - Bergen
torhelge.holmas@snf.no

July 4, 2007
Thanks to Gary M. Fournier, Tor Iversen, and two anonymous referees for valuable comments. The paper has benefited from being presented at the 7th European Health Economics Workshop in Konstanz, the HERO/HEB Health Economics Workshop in Oslo, and at seminars at the University of Bergen and the University of Minho. The usual caveat applies.
1 Introduction

Pharmaceutical markets are characterised by price inelastic demand, mainly due to extensive medical insurance, and supply-side market power associated with the patent system protecting new chemical entities from being copied within a given period.\(^1\) This combination has lead most countries to exert various means to control the growth in medical expenditures.\(^2\) Two of the most commonly used price control mechanisms in pharmaceutical markets are price cap regulation and reference pricing. While the two systems share the same purpose, namely to contain (the growth in) medical expenditures, they differ substantially in nature. Price cap regulation limits the pharmaceutical firms’ ability to exploit market power by charging high prices, while reference pricing aims at stimulating competition by making demand for pharmaceuticals more price elastic. The link between regulatory regimes and pharmaceutical firms’ pricing strategies has received surprisingly little attention in the literature, and the main purpose of this paper is to fill this gap.\(^3\)

We exploit a unique policy experiment from Norway to assess the relative performance of reference pricing and price cap regulation. In 2003 the Norwegian government introduced a reference price system called "index pricing" to a set of off-patent pharmaceuticals, replacing the existing price cap regime, which was based on international price comparisons. Since only a sub-sample of the off-patent drugs was exposed to reference pricing, the policy reform can be classified as a quasi-natural experiment. We exploit a rich product level panel dataset covering a four-year period from 2001 to 2005. Besides having data on all drugs exposed to the reference price system, we also have data on a substantial number of drugs still subject to the existing price cap regulation. This latter group of drugs consists of drugs that are either therapeutic substitutes or unrelated in consumption to the drugs exposed to reference pricing. In addition

\(^1\) A seminal contribution on the impact of insurance on the price elasticity of demand for prescription drugs is Leibowitz et al (1985), who exploit the Rand Health Insurance Experiment. A more recent contribution on this issue is Contoyannis et al. (2005). There are also studies that estimate the impact of marketing (e.g., Rizzo, 1999) on the price elasticities for prescription drugs.

\(^2\) The US is the exception among Western countries. However, the recent inclusion of prescription drugs in Medicare has spurred a debate of price controls also in the US (e.g., Huskamp et al, 2000, Kanavos and Reinhardt, 2003). In addition, (generic) reference pricing is well-established through the "maximum allowable charge" programs used by, e.g., Medicaid.

to exploiting the before-after reform variation in prices, we make use of the non-included drugs as a comparison group to identify the price effects on the drugs subject to the policy experiment, as well as any cross-price effects on therapeutic substitutes not exposed to the experiment.

Under price cap regulation, the regulator sets a maximum price that can be charged for each product. The price cap is set when a new patent-protected drug enters the market. To be effective (binding), the price cap needs to be lower than the firms’ profit-maximising (monopoly) price. Competition can, however, induce the firms to reduce the price on the original brand-name drug below the price cap level. First, if a new drug with similar therapeutic properties enters the market, the original drug can be forced to set a lower price to avoid losing too much of its market share. Second, when the original drug loses its patent protection, generic substitutes can enter the market with lower prices to capture market shares from the original drug. Our dataset allows us to identify the price effects due to therapeutic competition (first type) and generic competition (second type).

Under reference pricing, the regulator enforces no explicit restrictions on the pharmaceutical firms’ price setting. The firms are allowed to charge any price they like. Instead the regulator sets a maximum reimbursement price (the reference price) to be paid for a group of drugs ("clusters"). Purchase of drugs with price above the reference price results in a surcharge equal to the difference between the drug’s price and the reference price. This surcharge may be imposed by the regulator on the consumer, the prescribing physician, or, as in Norway, the dispensing pharmacy. The intention of reference pricing is to rectify the distortion in price sensitivity imposed by insurance, potentially resulting in lower prices and medical expenditures.

We find that the reference price system introduced in Norway has a strong price reducing effect on the drugs exposed to this regime, with the effect being stronger for brand-names (18 to 19 percent) than generics (7 to 8 percent). This confirms that reference pricing triggers price

---

4 We do not analyse the impact of (generic) entry on drug prices. This has been the subject of several papers, e.g., Caves et al. (1991), Grabowski and Vernon (1992), Frank and Salkever (1997).

5 The definition of clusters is a controversial issue. It is common to distinguish between generic and therapeutic reference pricing, where the former involves clustering of drugs that are chemically identical (generics), while the latter involves clustering of drugs that have similar therapeutic effects (therapeutic substitutes). We return to this issue in the next section.

6 Often the reference price is set equal to the lowest priced drug in the cluster. However, if this is not the case, the difference between the reference price and a lower priced drug is often shared between the payer and the dispensing pharmacy to create incentives to also sell those drugs (Lopez-Casanovas and Puig-Junoy, 2000).

7 The clustering of drugs, as defined by reference price regulation, might also provide information about substitutable drugs that can treat a particular disease, which in itself can increase the price sensitivity of demand.
competition within the cluster of drugs exposed to the regime. Since the reference price system in Norway included off-patent products only, the identified price effect is solely due to generic competition triggered by the reform.

Interestingly, we also identify a negative cross-price effect of the policy reform on the non-included therapeutic substitutes still under price cap regulation, providing evidence on therapeutic competition in the market. The effect is weaker (2.2 percent), as we would expect, since these drugs have different chemical substances and therefore are only imperfect substitutes to the drugs exposed to reference pricing. When we decompose the effect, we find that it is merely the generics that respond to the reform (by 6.4 percent). An obvious explanation is that the price cap is binding for the brand-names but not for the generics. This implies that we capture any price reductions on the generics, while for brand-names we observe only price reductions below the price cap. However, under free pricing, or less strict price regulation, it is likely that also the brand-names will reduce their prices as a response to the lower prices triggered by reference pricing.

The Norwegian policy experiment provides an excellent opportunity to assess the relative performance of two different regulatory regimes; reference pricing and price cap regulation. Our results suggest that reference pricing is more effective than price cap regulation in reducing drug prices. To indicate the economic significance of the reform, we can calculate potential savings in medical expenditures, using 2002, the year before the reform was introduced, as our benchmark. In 2002, the total sales value of the drugs included in the reference price system amounted to 474.4 mill NOK, with a brand-name market share of about 72 percent. Using our estimated price reductions of about 18 percent on brand-names and 8 percent of generics, we obtain cost saving of about 75 mill NOK. This is a conservative figure for two reasons. First, the reference price system is likely to trigger a shift in market shares from the brand-names to the generics (e.g., Aronsson et al., 2001). Second, when extending the reform to the whole generic market segment, the savings (in absolute terms) will be even higher.

A potential downside of the reference price system is related to the negative cross-price effect on non-included therapeutic substitutes. This raises a concern that reference pricing may reduce patent protection, which in turn can affect national launching decisions and global innovation incentives, especially if reference pricing becomes wide-spread and/or is implemented in large,
high-income countries.

The rest of the paper is organised as follows. In section 2, we relate our paper to existing literature. In section 3, we present institutional facts about the Norwegian pharmaceutical market, the regulatory regime and the policy reform introducing reference pricing. In section 4, we present a theoretical model to motivate our empirical study. In section 5, we present our dataset and some descriptive statistics. In section 6, we carry out the econometric analysis and report our empirical results. Finally, in section 7, concluding remarks are presented.

2 Related Literature

The literature on the performance of different regulatory regimes on pharmaceutical price setting is limited, and many of the empirical studies are descriptive. Our paper is a contribution in that respect. There are, however, some notable exceptions. Below we relate our paper to these.

In a theoretical paper, Danzon and Lui (1996) argues that all prices within the cluster will converge towards the reference price, implying a price decrease on the high-price (brand-name) drugs and a price increase on the low-price (generic) drugs, leaving the net price and cost saving effect of reference pricing unclear. Moreover, Zweifel and Grivelli (1997), who provide a theory model and some anecdotal evidence from Germany, suggest that reference pricing produces an immediate reduction in brand-name prices to the reference price level but has no effect on generics.

However, more recent studies, including ours, find a negative effect of reference pricing not only on brand-names but indeed also on generics. Aronsson et al. (2001) analyse how brand-name market shares are affected by generic competition, in general, and (generic) reference pricing, in particular. Using data from Sweden for the time period 1972-96, they find that the price of brand-name relative to the average price of generics affects the brand-name market share for 5 out of 12 different substances. Extending the model to capture the effect of the

---


9 This result relies on the assumptions that the reference price is set above the lowest price in the reference cluster and that demand is perfectly inelastic below the reference price. However, many countries set the reference price equal to the lowest price, and, those that don’t, often share the benefit from selling a drug with a price below the reference price with the dispensing pharmacy. Moreover, if there is coinsurance, demand is likely to be elastic also under the reference price. We return to this issue in Section 4.
reference price system introduced in 1993, they provide evidence that reference pricing has a negative effect on brand-name market share, but only for 3 substances. However, as the authors point out themselves, they have an identification problem because the reference price system is likely to affect the relative prices on brand-names and generics directly. They therefore perform a test on the price effects of reference prices, which indicates a strong negative effect on both brand-names and generics.

A more recent study by Bergman and Rudholm (2003), also based on Swedish data, analyses the impact of actual and potential competition between brand-names and generics, where ‘potential competition’ is defined as a situation where the brand-name’s patent has expired but no generics have entered. Using data on 18 substances for the same period as the previous study (1972-96), they find that the price of the brand-name is lowered by both actual and potential generic competition. They also find that the reference price system introduced in 1993 has a strong negative effect on brand-name prices (16-21 percent), but only for the drugs facing actual competition.

Pavcnik (2002), which is the closest study to ours, analyses the impact of the introduction of (therapeutic) reference pricing in Germany in 1989 on pharmaceutical prices, focusing on the change in patient out-of-pocket expenses. Using data on two different therapeutic fields (oral antidiabetics and antiulcerants) for the time period 1986-96, she identifies strong price decreases for both brand-names and generics, with the price reductions being more pronounced for the brand-names. She also finds that brand-names with more generic competitors reduce prices more.

Finally, there exists a recent paper by Dalen et al. (2006) analysing the same policy reform in Norway (the index price system) as we do. They use a structural approach, with prices as instruments, to estimate the impact of the reform on demand and market power, and concludes that the index price system increases the market shares of generic drugs and reduces overall market power. However, their dataset only covers the six chemical substances subject to the reference price system, as well as a limited number of pharmacies (22 of about 500).

The policy experiment in Norway enables us to advance the literature along several dimensions. First, it allows us to establish a proper comparison group to carefully estimate the net price effect of the reference price system. The previously mentioned studies resort to comparison
of prices and/or market shares before and after the introduction of reference pricing. In Sweden there was no policy experiment since all off-patent drugs were exposed to reference pricing in 1993. Dalen et al. (2006) could have made use of the policy experiment in Norway, but did not by focusing only on the drugs exposed to reference pricing. The exception is Pavcnik (2002) who exploits the gradually extension of the reference price system within the oral antidiabetic group in Germany to establish a comparison group. A potential problem with her comparison group is that it consists of therapeutic substitutes to the ones exposed to reference pricing, and, as our results show, there may be cross-price effects that can potentially bias the results.

Second, the policy experiment allows us to analyse generic and therapeutic competition. Generic competition has received substantial attention in the literature, possibly because of the so-called "generic paradox", where empirical studies have shown that brand-name drugs respond to generic entry by rising their prices (see e.g., Grabowski and Vernon, 1992, Frank and Salkever, 1997). The evidence from the Swedish market provided by Aaronsson et al. (2001) and Bergman and Rudholm (2003) and the German based study by Pavcnik (2002) do not support the "generic paradox" result. All studies find that generic entry or competition results in lower brand-name prices, which is also confirmed by our study. However, it is very likely that the difference in results may be due to different market structures and regulatory regimes in the US compared with European countries.

The literature on therapeutic competition is much more limited. An important exception is Ellison et al. (1997) that use US data from one therapeutic field (cephalosporin), providing evidence of high elasticities between generic substitutes and also significant, though lower, elasticities between therapeutic substitutes. Consistent with Ellison et al. (1997), we provide evidence of therapeutic competition in the pharmaceutical market, although this competition is, as one would expect, weaker than competition from generic substitutes.

Finally, our study also contributes to the debate on generic versus therapeutic reference pricing (see e.g., Lopez-Casasnovas and Puig-Junoy, 2000). Generic reference pricing (like in Norway and Sweden) is considered to be uncontroversial in contrast to therapeutic reference pricing (like in Germany) for two reasons: first, since generic reference pricing only includes

---

10 The "generic paradox" have been challenged by, for instance, Caves et al. (1991) who find that generic entry is associated with brand-name prices reductions. However, the reductions are economically small, much smaller than one would expect from products that are supposed to be perfect substitutes.
drugs with the same active chemical substances, it should not expose patients to any health risks. Second, since generic reference pricing applies by definition to off-patent drugs only, it is perceived to not affect patent protection, and thus launching and innovation incentives.

A recent theoretical paper by Brekke et al. (2007) challenges the "innocence" of generic reference pricing. They show that the price reductions on the drugs exposed to generic reference pricing triggers price reductions also on non-included (potentially on-patent) therapeutic substitutes. They also show that generic reference pricing result in larger co-payment differences between the referenced drugs and their therapeutic substitutes, resulting in more therapeutic substitution and thus higher patient health risks than therapeutic reference pricing.

Our data does not enable us to test the effect of reference pricing on the patients' health risk or the market entry and innovation incentives of the firms. However, we provide evidence on a negative cross-price effect of the generic reference price system on therapeutic substitutes not subject to this system. This confirms the concern raised by Brekke et al. (2007) that not only therapeutic reference pricing but also generic reference pricing may reduce patent protection and potentially expose patients to health risks.

3 The Norwegian Pharmaceutical Market

The Norwegian pharmaceutical market is extensively regulated, as in most other countries. The regulatory body is the Norwegian Ministry of Health and Care Services and its agency called the Norwegian Medicines Agency. Norway has adopted the European patent law system to a large extent, implying that all new chemical entities are subject to patent protection for a given period. However, the pharmaceutical firms still need government approval to launch a new product in Norway. In addition, they must submit an application providing sufficient evidence of benefits compared with costs from the drug therapy in order to get the drug listed in the reimbursement system (the blue list). Once this is obtained, the prices are subject to price control.

The current system is a price cap scheme based on international reference pricing, also

---

11 A paper by Danzon and Ketchham (2004) analyses the effect of reference pricing on the availability of drugs in Germany, the Netherlands and New Zealand, providing results that indicate that the strictness of the reference price systems tends to lower the number of drugs available in a country.
called external referencing. This system was introduced in 2001, and covers all prescription drugs, both on-patent and off-patent, except for those included in the reference price system. The government requires that a producer (say Pfizer) that sells a prescription drug (say Lipitor) on the Norwegian market, reports the foreign prices of this drug in a defined set of "comparable" countries.\(^\text{12}\) The price cap, which is the maximum domestic price a producer can charge for its product, is then set equal to the average of the three lowest reported foreign prices of this drug. Generic versions receive the same price cap as the brand-names, implying that the price cap rarely binds for this group of drugs. The price cap is imposed at the wholesale level, leaving the producer prices unregulated. The government then defines a maximum mark-up the pharmacies can charge, which in turn determines the price cap on the retail price for each product.

The reference price system, called index pricing, was introduced in March 2003 for a subsample of off-patent pharmaceuticals facing generic competition. Initially, the index price system covered six chemical substances: Citalopram (depression), Omeprazol (antiulcer), Cetirizin (allergy), Loratadin (allergy), Enalapril (high blood pressure) and Lisinopril (high blood pressure). In June 2004 Simvastatin (high cholesterol) was included. The choice of drugs were based on two criteria: first, they should cover a wide set of diseases, and not be concentrated in one particular disease type; second, the selected drugs should be high-volum drugs in terms of sales.\(^\text{13}\) The government decided to terminate the system by the end of 2004, arguing that the price reductions and cost savings were lower than expected.\(^\text{14}\) Thus, in total the system run for almost two years.

The government calculated the index price as follows. First, the drugs were classified into clusters based on chemical substance. Then within each cluster, the drugs were classified into subgroups depending on the package size and dosage in order to adjust for cost variation. Second, the index price was calculated as the sales weighted sum of producer prices of the drugs included

\(^{12}\)The Norwegian basket of "comparable" countries consists of Austria, Belgium, Danmark, Finland, Germany, Ireland, the Netherlands, Sweden and the UK. Southern and Eastern European countries, as well as France and Switzerland, are excluded. If the product is not yet launched in any of the countries in the basket, the price cap will be determined by negotiations between the producer and the regulator.

\(^{13}\)The first criteria is helpful for identification purposes since it provides us with proper control groups. The second criteria could potentially be a problem if the selected drugs differ from the non-selected drugs in price patterns. We therefore explicitly test whether this is the case, and report our results in Section 6.2, Table 3.

\(^{14}\)The decision was based on an evaluation report, using data until February 2004. As will be shown below, our analysis strongly indicates that the evaluation was carried out too early. Price reductions became substantial after some time, especially during 2004.
in each subgroup. For the six chemical substances initially included, there were 16 index prices in total. The government repeated this exercise every three months, resulting in a revised index price for every quarter of a year. Formally, the index price for a given period $t$, denoted by $I^t$, used by the government can be written as followed:

$$I^t = \sum_{i=1}^{N} \left[M_{i}^{t-1} \cdot p_{i}^{t-1}\right], \text{ where } M_{i}^{t-1} = \frac{q_{i}^{t-1}}{\sum_{j=1}^{N} q_{j}^{t-1}}.$$ 

where $p_{i}^{t-1}$ is the producer price of product $i$ in the previous period ($t-1$), $q_{i}^{t-1}$ is the quantity sold of product $i$ in the previous period, measured in tablets or defined daily doses (DDD), and, thus, $M_{i}^{t-1}$ is the market share of product $i$ in the previous period. Since each period $t$ lasts for three months, all variables are average values. The index price was the maximum reimbursement for every drug in the reference group. We see that the index price is reduced if lower-priced (generic) drugs increase their market share, and/or if there is a price decrease of the higher-priced (brand-name) drugs and/or the lower-priced (generic) drugs generic in the cluster.

A special feature of the Norwegian reference price system relative to other reference price systems is that the pharmacies were exposed to all incentives. Not only did they keep the margin of selling a (generic) drug with a price lower than the index price, but they also had to bear the full cost of selling a (brand-name) drug with a price higher than the index price. Importantly, generic substitution was allowed in 2001, so the pharmacies could suggest a cheaper (generic) drug, although the physicians had written a brand-name drug on the prescription (which they frequently tend to do). If the patients refused to accept a generic substitution, they had to pay the surcharge associated with the difference between the high-priced (brand-name) drug and the index price, as is common in most other reference price systems. On the other hand, the physicians could blockade generic substitution by actively writing an argument on the prescription of why this particular patient is better off with the brand-name drug. In such cases, the price cap system was reintroduced.

In Norway there is a statutory public health insurance, covering the whole population. Close to 70 percent of the total drug expenses are covered by this insurance scheme. For prescription drugs on the reimbursement list (the blue list), patients pay a fixed share (36 percent) of the drug
price, constrained by a maximum amount per prescription (400 NOK) and per calendar year (1,350 NOK). Notably, the index price system did not change the structure of the patient out-of-pocket payments, except for the case when the patients refused to accept a cheaper generic drug, as described above. However, the amount of the patient out-of-pocket payments may, of course, be affected to the extent that the reference pricing affects prices and choices of pharmaceuticals.

4 A Theoretical Model

To motivate our empirical analysis, we present a theoretical model focusing on the impact of regulatory regimes on pharmaceutical price setting. Consider a particular therapeutical market with an original brand-name drug (drug B) facing competition from a generic version (drug G). Consumers are (partially) insured and face a co-payment \( c_i \) when demanding drug \( i \), where \( i = B, G \). Demand for drug \( i \), given by \( D_i(c_B, c_G) \), is decreasing in the co-payment for drug \( i \), but increasing in the co-payment for drug \( j \), i.e., \( \partial D_i / \partial c_i < 0, \partial D_i / \partial c_j > 0 \). We let firm \( i \)'s (gross) profit be given by \( \pi_i = p_i D_i(c_B, c_G) \), where \( p_i \) is the price charged for drug \( i \). In line with empirical observations, we assume the demand structure is such that the brand-name firm is able to charge a higher price than the generic firm without losing all demand. Implicitly, this means that the two products cannot be perceived as perfect substitutes despite being therapeutically equivalent.\(^{15}\)

**Price Cap Regulation (PC).** Under price cap regulation the regulator imposes a maximum price, \( \hat{p} \), the firms can charge for their products. Consistent with empirical observations, we let the price cap be binding for the brand-name drug only, i.e., \( p_B = \hat{p} \). We assume that \( c_i \) takes the form of coinsurance, i.e., \( c_i = \alpha p_i \), where \( \alpha \in (0, 1) \) is the coinsurance rate defining the cost-sharing between the patient and the payer. We then get the following first-order condition defining the optimal generic price:

\[
\frac{\partial \pi_G}{\partial p_G} = D_G(\alpha \hat{p}, \alpha p_G) + \alpha p_G \frac{\partial D_G(\alpha \hat{p}, \alpha p_G)}{\partial c_G} = 0, \tag{1}
\]

\(^{15}\)The existing theoretical contributions on branded vs generic competition – e.g., Frank and Salkever (1992), Brekke et al (2007), Königbauer (2007) – apply explicit asymmetric demand systems that result in higher brand-name than generic prices. They also provide detailed justifications (e.g., brand-name marketing, consumer experience/information, prescribing habits, etc.) for the asymmetry in brand-name and generic demand.
The impact of a change in the price cap on the generic price can be derived by total differentiation of (1). In general form, we can write this as follows:

$$\frac{\partial p_G}{\partial \bar{p}} = -\frac{\partial^2 \pi_G / \partial \bar{p} \partial p_G}{\partial^2 \pi_G / \partial p_G^2} > 0,$$

Assuming that the second-order condition is satisfied (negative denominator) and that prices are strategic complements (positive numerator), there is a positive relationship between the price cap and the generic price. Thus, a stricter price cap directly reduces the brand-name price, and indirectly induces the generic firm to lower its price in order to maintain market shares, and vice versa. We therefore expect to observe a positive relationship between the price cap and prices for both brand-names and generics.\(^{16}\)

**Reference Pricing (RP).** Under reference pricing, the pharmaceutical firms are free to set their prices at any level. The regulator imposes instead a reference price \(\bar{p}\), which is the *maximum reimbursement* for a group of drugs with similar therapeutic properties (here: drug \(B\) and \(G\)). The reference price is set somewhere between the brand-name and the generic price, i.e., \(p_G < \bar{p} < p_B\). A central feature of reference pricing is that a patient demanding (or a pharmacy dispensing) a high-priced brand-name drug, will have to cover the price difference, i.e., \(c_B = \alpha \bar{p} + (p_B - \bar{p})\). The first-order conditions for the brand-name and the generic firm are:

\[
\frac{\partial \pi_B}{\partial p_B} = D_B [\alpha \bar{p} + (p_B - \bar{p}), \alpha p_G] + p_B \frac{\partial D_B [\cdot]}{\partial c_B} = 0, \tag{2}
\]

\[
\frac{\partial \pi_G}{\partial p_G} = D_G [\alpha \bar{p} + (p_B - \bar{p}), \alpha p_G] + \alpha p_G \frac{\partial D_G [\cdot]}{\partial c_G} = 0, \tag{3}
\]

respectively. We see from (2) that the coinsurance rate \(\alpha\) is not a part of the second term, implying a higher demand responsiveness to price changes for the brand-name drug. Since reference pricing imposes a higher brand-name co-payment, brand-name demand is also lower for given prices. Thus, reference pricing introduces an incentive for the brand-firm to lower its price in order to maintain market shares.

The incentives for the generic firm are, however, less clear. Reference pricing implies, all

\(^{16}\)However, if the price cap is set very strict, generic drugs might exit (or not enter) the market, which could potentially result in higher average prices. Danzon and Ketchham (2004) provide evidence that generic competition is weaker in countries with strict price regulation.
else equal, a higher brand-name co-payment, which shifts consumers toward the generic firm. Facing a higher demand, it is optimal for the generic firm to increase its price. However, since the brand-name firm responds to reference pricing by lowering its price, the net effect on brand-name co-payment is ambiguous. Our model predicts, thus, that if reference pricing leads to a lower (higher) equilibrium brand-name co-payment, this will trigger a reduction (increase) in the price of the generic drug.17

The ranking of price cap and reference price regulation in terms of price levels is in general ambiguous. More precisely, the ranking will depend on the strictness of the price cap $\tilde{p}$ relative to reference price level $\tilde{p}$. Clearly, if the price cap is very strict (e.g., close to marginal production costs), there is limited scope for reference pricing to reduce prices further. A switch from price cap regulation to reference pricing implies by definition that the reference price is set below the price cap, i.e., $\tilde{p} < \tilde{p} = p_{PC}^B$ (in practice, often close to the generic price, $\tilde{p} \rightarrow p_{PC}^G$). Thus, our prediction is that reference pricing leads to lower drug prices if the reference price is set sufficiently low relative to the initial price cap level.

To summarise, the following predictions can be derived from the model:

1. There is a positive relationship between the price cap and brand-name and generic prices.
2. Reference pricing provides an incentive for the brand-name to reduce prices, while the incentive to reduce generic prices is weaker, potentially ambiguous.
3. Reference pricing leads to lower prices than price cap regulation only if the reference price is sufficiently low relative to the price cap level.

5 Data and Descriptive Results

5.1 Data

In the empirical analysis we use data from Farmastat.18 Their database includes information on sales value and volume for each package of drugs sold at the Norwegian pharmaceutical market. Values are in pharmacy purchase prices and volumes in defined daily doses (DDD) for the active

\[ p_{PC}^{RP} < p_{PC}^{G} \text{ iff } c_{PC}^{RP} < c_{PC}^{G} \iff p_{PC}^{RP} - (1 - \alpha) \tilde{p} < \alpha \tilde{p}. \]

\[ 18 \text{ Farmastat is a company specialised in provision of pharmaceutical statistics. The company is owned by the Norwegian Association of Pharmaceutical Manufacturers.} \]
substance according to the ATC-code system. The database also provides information about product name, manufacturer, launch date, price cap, whether the product is a brand-name or a generic drug, package size and dosage.

Table 1. Sample Characteristics

<table>
<thead>
<tr>
<th>ATC-group</th>
<th>Drug subject to reference pricing</th>
<th>Therapeutic competitor</th>
<th>Brand name</th>
<th>Manufacturer</th>
<th>Number of generics</th>
<th>Number of observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>A02BA02</td>
<td>No</td>
<td>Yes</td>
<td>ZANTAC</td>
<td>GLAXOSMITHKLIN</td>
<td>5</td>
<td>254</td>
</tr>
<tr>
<td>A02BC01</td>
<td>Yes</td>
<td>No</td>
<td>LOSEC</td>
<td>AstraZeneca</td>
<td>1</td>
<td>86</td>
</tr>
<tr>
<td>A02BC03</td>
<td>No</td>
<td>Yes</td>
<td>LANZO</td>
<td>Wyeth-Lederle</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>A02BC05</td>
<td>No</td>
<td>Yes</td>
<td>NEXIUM</td>
<td>AstraZeneca</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>C07AB02</td>
<td>No</td>
<td>No</td>
<td>SELO-ZOK</td>
<td>AstraZeneca</td>
<td>3</td>
<td>109</td>
</tr>
<tr>
<td>C07AB03</td>
<td>No</td>
<td>No</td>
<td>TENOGLYNE</td>
<td>AstraZeneca</td>
<td>5</td>
<td>242</td>
</tr>
<tr>
<td>C09AA02</td>
<td>Yes</td>
<td>No</td>
<td>RENITEC</td>
<td>MSD</td>
<td>3</td>
<td>131</td>
</tr>
<tr>
<td>C09AA03</td>
<td>Yes</td>
<td>No</td>
<td>VIVATRIAC</td>
<td>AstraZeneca</td>
<td>4</td>
<td>205</td>
</tr>
<tr>
<td>C09BA02</td>
<td>No</td>
<td>Yes</td>
<td>RENITEC</td>
<td>MSD</td>
<td>1</td>
<td>72</td>
</tr>
<tr>
<td>C09CA01</td>
<td>No</td>
<td>Yes</td>
<td>COZAAR</td>
<td>MSD</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>C09DA01</td>
<td>No</td>
<td>Yes</td>
<td>COZAAR</td>
<td>MSD</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>C10AA01</td>
<td>Yes (1.6.2004)</td>
<td>No</td>
<td>ZOCOR</td>
<td>MSD</td>
<td>2</td>
<td>82</td>
</tr>
<tr>
<td>C10AA03</td>
<td>No</td>
<td>Yes</td>
<td>PRAVACHOL</td>
<td>B-Myler Squibb</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>C10AC05</td>
<td>No</td>
<td>Yes</td>
<td>LIPITOR</td>
<td>Pfizer</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>G04BE03</td>
<td>No</td>
<td>No</td>
<td>VIAGRA</td>
<td>Pfizer</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>L02BB03</td>
<td>No</td>
<td>No</td>
<td>CASODEX</td>
<td>AstraZeneca</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>M10AH01</td>
<td>No</td>
<td>No</td>
<td>CELEBRA</td>
<td>Pfizer</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>M10AH02</td>
<td>No</td>
<td>No</td>
<td>VIOXX</td>
<td>MSD</td>
<td>0</td>
<td>45</td>
</tr>
<tr>
<td>M05BA04</td>
<td>No</td>
<td>No</td>
<td>FOSAMAX</td>
<td>MSD</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>N02BE01</td>
<td>No</td>
<td>No</td>
<td>PANODIL</td>
<td>GLAXOSMITHKLIN</td>
<td>4</td>
<td>240</td>
</tr>
<tr>
<td>N02CC01</td>
<td>No</td>
<td>No</td>
<td>IMIGRAN</td>
<td>GLAXOSMITHKLIN</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>N05AH03</td>
<td>No</td>
<td>No</td>
<td>ZYPREXA</td>
<td>ELI LILLY</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>N06AB04</td>
<td>Yes</td>
<td>No</td>
<td>CIPRAMIL</td>
<td>Lundbeck</td>
<td>3</td>
<td>112</td>
</tr>
<tr>
<td>N06AB05</td>
<td>No</td>
<td>Yes</td>
<td>SEROXAT</td>
<td>GLAXOSMITHKLIN</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>N06AB06</td>
<td>No</td>
<td>Yes</td>
<td>ZOLOFT</td>
<td>Pfizer</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>N06AX03</td>
<td>No</td>
<td>Yes</td>
<td>TOLVON</td>
<td>Organon</td>
<td>1</td>
<td>96</td>
</tr>
<tr>
<td>R03AK06</td>
<td>No</td>
<td>No</td>
<td>SERETOIDE</td>
<td>GLAXOSMITHKLIN</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>R03AK07</td>
<td>No</td>
<td>No</td>
<td>SYMBICORT</td>
<td>AstraZeneca</td>
<td>0</td>
<td>44</td>
</tr>
<tr>
<td>R06AE07</td>
<td>Yes</td>
<td>No</td>
<td>REACTINE</td>
<td>Pfizer</td>
<td>3</td>
<td>151</td>
</tr>
<tr>
<td>R06AX13</td>
<td>Yes</td>
<td>No</td>
<td>CLARITYN</td>
<td>Schering-Ploough</td>
<td>4</td>
<td>176</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>37</td>
<td>2765</td>
</tr>
</tbody>
</table>

From this database we have data on all prescription drugs within the 30 largest ATC-groups (in terms of sales value) over a four year period from 2001 through 2004. Table 1 lists ATC-code, brand-name, and manufacturer of these pharmaceuticals. The table also gives information about

---

19 The ATC-code system is used by the World Health Organization to classify pharmaceutical substances according to their chemical, pharmacological and therapeutic properties. Pharmaceuticals sharing the same seven-figure ATC-code have the same active ingredients and are considered equivalent in the treatment of a given disease.
whether the drugs within each ATC-code are subject to reference pricing, whether the branded drug faces generic competition, and whether a drug is classified as a therapeutic competitor to a drug in the reference price group. This last classification is based on therapeutic categories. For example, Losec with ATC-code A02BC01 is included in the index price system, and therefore all pharmaceuticals with A02 as the first three characters in the ATC-code are classified as therapeutic competitors to Losec.\textsuperscript{20}

In our analysis, we define a product as all presentations of a given drug produced by a given manufacturer. For example, the brand-name Zantac together with five generic products give a total of six products in ATC-group A02BA02. For each product, prices are calculated as total sales values divided by the total volume sold (in DDD). All prices therefore refer to average prices per defined daily dose of the active ingredient; a price measure that enables comparison across different formulations (tablets, capsules, etc.) within each product, and also across different active ingredients. The prices have been deflated using the consumer-price index. Time is measured in one-month periods, and the average price of each product in each time-period constitutes an observation. The number of observations is not identical in each period, which is due to generic entry during our sample period. In such cases, the product does not appear in our data, leaving us with an unbalanced panel. The number of observations within each ATC-group is given in the last column in Table 1. The total number of observations in our analysis is 2765.

\textbf{5.2 Descriptive results}

A natural starting point for the descriptive analysis is to look at how average prices have developed over time. In Figure 1, we plot average prices for brand-names and generics for the following three groups of pharmaceuticals: (i) the pharmaceuticals subject to reference pricing, (ii) the drugs that are therapeutic substitutes still under price cap regulation, and (iii) the others, which are independent in consumption and exposed to price cap regulation.

\textsuperscript{20}Our definition of therapeutic substitutes follows the standard in the literature (see e.g., Pavcnik, 2002, and Ellison et al., 1997). With this definition, we still have a subgroup of drugs within the C07-group that can be regarded as therapeutic substitutes for some C09-drugs for a limited set of conditions. Including the C09-group among the therapeutic substitutes in the regressions only marginally alter the coefficient estimates. The estimated effects of the reform remain unaltered.
With time measured in one-month periods, the reference price regulation was introduced in period 27 in the figure. Average prices of pharmaceuticals subject to reference pricing display a pronounced decrease after the implementation of the reform. In Table 2, we have calculated the average price in the periods before and after the implementation of the index price system.

**Table 2. Average prices before and after reference pricing.**

<table>
<thead>
<tr>
<th></th>
<th>Prices before</th>
<th>Prices after</th>
<th>Percentage price change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug subject to reference pricing</td>
<td>4.66 (3.18)</td>
<td>3.48 (2.23)</td>
<td>-25.32%</td>
</tr>
<tr>
<td>Therapeutic competitors</td>
<td>6.95 (2.78)</td>
<td>6.09 (2.55)</td>
<td>-12.37%</td>
</tr>
<tr>
<td>Other drugs</td>
<td>14.21 (16.89)</td>
<td>14.05 (16.34)</td>
<td>-0.01%</td>
</tr>
</tbody>
</table>

We find that average prices in the pre-regulation period is about 4.7 NOK, while average prices during reference pricing is about 3.3 NOK. This implies a price reduction of more than 29 percent. Turning to the therapeutic competitor group, we find a somewhat similar price pattern as in the group of pharmaceuticals subject to reference pricing prior to the reform, but the
Figure 2: Average prices of brand-names and generics in the reference pricing group

decrease in average prices after the reform is much smaller, about 12 percent. The average prices in the “others” group show a quite different price pattern; a large decline in the first part of the reference price period is followed by an increase in the second part of this period.

To get a better understanding of the price patterns depicted in Figure 1, we plot the average prices of brand-names and generics together with the average price cap for the three groups. In Figure 2, we see that prior to the reform changes in the average price of the brand-name drugs are related to changes in the price cap. After implementation of the reference price regulation the average price of the brand name drugs has been steadily decreasing. Interestingly, in the post-regulation period, average prices of generic drugs follow almost the same price pattern as brand-name pharmaceuticals. The large variation in the average price of the generics in the period before the reform is almost entirely due to entry of new generic drugs. In Figure A1 in the Appendix, we have plotted the same average prices as in Figure 2, but only included generics that have been in the market during the entire sample period. From this figure, we see that the average price of generics follows the same trend as the average prices of brand-names.

From Figure 3 and 4 we see that average prices of brand-names in the therapeutic competitor group and the “others” group follow the maximum price over the entire period. This indicates
Figure 3: Average prices of brand-names and generics in the therapeutic competitor group

Figure 4: Average prices of brand-names and generics in the “others” group
that the reference price regulation had a small, if any effect on the price setting of brand-name drugs in the group of pharmaceuticals not directly affected by the regulation. However, average prices of generic drugs in the therapeutic competitor group follow the same pattern as prices for generics in the reference pricing group, which indicates that much of the price reduction in the "therapeutic competitor" group is explained by a reduction in prices on generic drugs. An obvious reason is that the price cap is binding for the brand-names but not for the generics. As a consequence, we will observe any price reduction on the generics, while for brand-names we observe only price reductions below the price cap.

In Figure 5 we have plotted the (average) amount of brand-name and generic drugs, measured in DDDs, sold in each month during the observation period. Over time, also before the reform, we see a gradual increase in the sales of generic substitutes. The strong increase in the sales of branded products in February-April 2001 is not as strong during the same months one year later. Instead sales of generics increase more. During the months when the reference pricing system is in work the difference in market shares between branded and generic products is considerably

---

<table>
<thead>
<tr>
<th>0</th>
<th>50</th>
<th>100</th>
<th>150</th>
<th>200</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>6</td>
<td>12</td>
<td>18</td>
<td>24</td>
</tr>
</tbody>
</table>

Figure 5: Average sales (in DDD) of brand-names and generics in the reference pricing group

---

21 The repeated sharp peaks followed by steep drops in sales that arise each year in December (peak) and January (drop) can be explained by the cap on consumer out-of-pocket expenditures of NOK 1350 per year. As further expenditures within the calendar year are fully reimbursed by the public health insurance scheme, consumers stockpile drugs by the end of the calendar year. Besides from that, the curves also show some seasonal variation in drug consumption.
reduced. This corresponds well with the results presented in Aronsson et al. (2001) and Dalen et al. (2006).

6 Empirical Analysis

6.1 Design and econometric model

The descriptive statistics presented in Section 5 suggest a strong, negative price response on pharmaceuticals subject to reference pricing. There are also some indications of a negative cross-price effect of the reform on non-included therapeutic competitors. In this section, we present an econometric framework to analyse the price effects of the reform more carefully. Ideally, in order to estimate the effect of introducing reference pricing, we would like to know what the prices on the products affected by the reform would have been had the reform not been imposed on them. Since we only observe prices for these products with the imposed reform, we let the prices from a set of other comparable products represent the counterfactual. Having panel data, we are able to compare inter-temporal variation in prices before and after the imposition of the reform. Therefore, identification relies not only on before-after comparison, but also on comparison of price variation for drugs subject to the reform with price variation for comparable drugs not subject to the reform.

Our econometric framework is based on an application of a model used in numerous evaluation studies (e.g., Ashenfelter 1978; Card and Sullivan 1988; Lavy 2002; Pavcnik 2002), where (permanent) unobserved differences between pharmaceuticals are controlled for by including product fixed effects in the model. Following the convention from this literature, we use the notion ‘treatment group’ for the pharmaceuticals subject to reference pricing, while pharmaceuticals not subject to the reform are used as a comparison group.

In this section, we closely follow Lavy (2002) and Pavcnik (2002). Let the dummy variable $D_{it}$ indicate treatment status for a given product, and let $P_{it}(0)$ indicate the price of product $i$ in period $t$ if the product is not exposed to treatment ($D_{it} = 0$). The fixed effect model then implies that the price of any untreated product $i$ at time $t$ can be written as

$$P_{it}(0) = X'_{it}\beta + a_i + \delta_t + \varepsilon_{it}.$$  (4)
Here, \( a_i \) is a product fixed effect, \( \delta_t \) is a period specific effect common to all products, \( \varepsilon_{it} \) represents unobserved time varying factors that affect prices, and \( X'_{it} \) contains observable variables. In the model, the error term \( \varepsilon_{it} \) is allowed to be correlated with \( a_i \), but not with the treatment status \( D_{it} \).

We estimate the average price effect of the reform, measured by \( \alpha \). The post-reform prices for pharmaceuticals subject to reference pricing becomes: \( P_{it} (1) = P_{it} (0) + \alpha \). Hence, the observed price for product \( i \) in time period \( t \) can be written as

\[
P_{it} = X'_{it} \beta + a_i + \delta_t + \alpha D_{it} + \varepsilon_{it},
\]

where the error term \( \varepsilon_{it} \) is assumed to be uncorrelated with \( D_{it} \) as well as with \( X'_{it} \) and \( \delta_t \). This assumption has several testable implications: first, any price differences prior to the reform between products in the treatment group and products in the comparison group can be explained by observable variables and the product specific effect \( a_i \). Second, after controlling for observables and the product specific effects, the price trend for drugs in the comparison group should not be significantly different in the post-reform period compared with the pre-reform period.

Since \( D_{it} \) is an interaction term\(^{22}\) equal to 1 for products and periods subject to the reform and 0 for all other drugs, then \( \alpha \) is the estimated total effect of introducing reference pricing. However, previous studies have found that prices on brand-names and generics adjust differently to price regulations (e.g., Aronsson et al., 2001, Pavcnik, 2002). To distinguish between brand-names and generics, we therefore interact \( D_{it} \) with a dummy \( B_i \) that equals 1 if product \( i \) is a brand-name.

We are also interested in whether there is a cross-price effect of reference pricing on therapeutic competitors. Pharmaceuticals with different chemical compounds but similar therapeutic effects are typically substitutes in treatment. It is therefore likely that price responses triggered by the reference price system may influence the pricing of non-included therapeutic substitutes.\(^ {23}\)

---

\(^{22}\) For products within six of the seven therapeutic substances subjected to the reference price system, this variable equals zero for period \( t = 1, \ldots, 26 \), and one for period \( t = 27, \ldots, 48 \). For products within the seventh substance, that was included as of June 2004, the variable equals zero up to period \( t = 41 \) and one thereafter.

\(^{23}\) Ellison et al. (1997) provide evidence of negative price elasticities between drugs with different chemical compounds but therapeutically similar effects.
To estimate such effects, we introduce the variables $DTC_{it}$ and $DTC_{it} * B_i$, where $DTC_{it}$ is the interaction between a dummy indicating observations in the post-reform periods and a dummy indicating whether or not a product is a therapeutic competitor. After taking the natural log of prices, our estimating equation thus becomes

$$\ln P_{it} = X'_{it} \beta + a_i + \delta_t + \alpha_1 D_{it} + \alpha_2 D_{it} * B_i$$

$$+ \alpha_3 DTC_{it} + \alpha_4 DTC_{it} * B_i + \varepsilon_{it}. \quad (6)$$

Note that we by this specification have two different treatment groups. The first group consists of pharmaceuticals subject to reference pricing, the second group of their therapeutic competitors, while the drugs in the "others" group serve as our comparison group. Excluding the therapeutic competitors from the comparison group enables us to capture potential cross-price effects, and also ensures that the comparison group consists of drugs not affected by the reform. In the next section, we conduct tests that provide evidence that the "others" group is a valid comparison group.

The direct price effect of the reform is measured by $\alpha_1$ and $\alpha_2$. $\alpha_1$ is the estimated price effect of the reform on generics subject to reference pricing, $\alpha_2$ measures whether reference pricing influences brand-names differently than generics, and thus $\alpha_1 + \alpha_2$ is the price effect on brand-names subject to the reform. In a similar way, the two coefficients $\alpha_3$ and $\alpha_4$ measure the cross price effect of the reform on brand-names and generics in the therapeutic competitor group.

Within equation (6), $a_i$ control for time constant product specific factors (both observed and unobserved) that affect prices, while the period specific effect, $\delta_t$, control for time-varying factors that affect prices equally for all pharmaceuticals. $X'_{it}$ consists of variables controlling for price cap regulation and the degree of competition. To control for price cap regulation, we include the natural log of the average price cap faced by product $i$ at time $t$, $\ln PCAP$. From the figures in Section 5, we see that the brand-name prices follow the price cap level quite closely. Since the price cap is binding for the brand-names, we expect the sign of this variable to be positive; a lower price cap yields lower average prices, and vice versa. By including the price cap in our regressions, we ensure that the estimated effect of the reference price system is directly
compared with the price cap regime.\textsuperscript{24}

To control for the degree of competition, we calculate the Herfindahl index, measuring the degree of concentration within a therapeutic substance group. The Herfindal index will be maximised (take the value of 10.000) in case of only one product within substance group, capturing that a drug is still under patent protection and/or there is no (generic) competition. As competition increases, the index becomes lower. We therefore expect the estimated coefficient to have a positive sign, i.e., that higher market concentration support higher prices.

6.2 Empirical Results

As noted in the previous section, our estimating strategy relies on that drugs in the comparison group are "comparable" to drugs in the treatment groups, except for not being treated. Even though the figures in section 5 showed quite similar price trends for all three groups of pharmaceuticals prior to the reform, this assumption should be tested more thoroughly. We therefore start out this section by presenting results from two tests of the comparison group: first, in the pre-reform period, after controlling for covariates and product specific effects, the price trends for pharmaceuticals subject to reference pricing should not be different from the price trends for pharmaceuticals not included in the reform. Second, after controlling for covariates and product specific effects, the price trends for pharmaceuticals in the comparison group should not be different in the post-reform period compared with the pre-reform period.

In the first test, we run regressions on pre-reform data, where we regress log prices on period dummies and period dummies interacted with a dummy variable indicating treated products. We also control for changes in the price cap level, the degree of competition and product specific effects. If the interactions are jointly insignificant, this is an indication of a legitimate control group, i.e., that unobservable factors affecting price setting are uncorrelated with the probability that a given product is in the treatment group. In column 1-3 in table 3, we present results where price trends for pharmaceuticals subject to reference pricing are compared with price trends for pharmaceuticals in the control group (others group). The first model uses the period just prior to the reform (period 26) as the base group, the second model uses period 13 as the base group,

\textsuperscript{24} As explained in Section 3, the price caps were still calculated for the drugs subject to reference pricing in case the physicians restricted generic substitution or the patients refused to purchase a cheaper generic drug.
and in the third model we use the first period in our dataset as the base group. The three last columns in table 3 give similar comparisons of the therapeutic competitors and the comparison group. Despite a few significant interactions in model 3 and 6, we find the results from these regressions quite conclusive due to the fact that joint insignificants of the interactions are not rejected in any model.

In the second test, we restrict our sample to pharmaceuticals in the comparison group and regress log prices on a dummy variable equal to 1 for the post-reform period and 0 otherwise. In the regression, we control for period dummies, the price cap level, the degree of competition, and a product specific effects. Results presented in table 4, show that the dummy variable has no significant effect on prices, and clearly indicates that price trends for drugs in the comparison group are not affected by the reference pricing reform. On the basis of the results from these tests, we conclude that the "others" group is a legitimate comparison group.

We start out by estimating a fixed effect model based on a simple version of equation (6), where we focus on pharmaceuticals exposed to reference pricing only, not distinguish between brands and generics.\textsuperscript{25} We see from model 1 in table 5 that the estimated effect of the reform is a price reduction of about 24 percent. Not surprisingly, this is in line with the results reported in table 2, where we compared the average prices before and after the introduction of the reference price system. In model 2, we allow for brand-names and generics to be affected differently by the reform. Similar to Aronsson et al. (2001) and Pavcnik (2002), our results show that reference pricing triggers a stronger price reduction on brand-names (30 percent) than generics (19 percent). This is also in line with our second prediction from the theory section.

\textsuperscript{25}In the models in table 4, we have tested for three different time specifications; year dummies, period dummies and a time trend variable. In terms of R-squared, we found that the best specification was the one with period dummies.
Table 3. Testing for pre-reform differences in price trends between groups of products. Fixed effect results with robust standard errors.

<table>
<thead>
<tr>
<th>Reference price group vs. others group</th>
<th>Therapeutic competitors vs. others group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1)</td>
</tr>
<tr>
<td>Interaction period 1</td>
<td>.043 (.045)</td>
</tr>
<tr>
<td>Interaction period 2</td>
<td>.026 (.044)</td>
</tr>
<tr>
<td>Interaction period 3</td>
<td>.031 (.043)</td>
</tr>
<tr>
<td>Interaction period 4</td>
<td>.057 (.046)</td>
</tr>
<tr>
<td>Interaction period 5</td>
<td>.023 (.041)</td>
</tr>
<tr>
<td>Interaction period 6</td>
<td>.016 (.042)</td>
</tr>
<tr>
<td>Interaction period 7</td>
<td>.008 (.040)</td>
</tr>
<tr>
<td>Interaction period 8</td>
<td>.007 (.040)</td>
</tr>
<tr>
<td>Interaction period 9</td>
<td>.009 (.039)</td>
</tr>
<tr>
<td>Interaction period 10</td>
<td>.009 (.039)</td>
</tr>
<tr>
<td>Interaction period 11</td>
<td>.056 (.056)</td>
</tr>
<tr>
<td>Interaction period 12</td>
<td>.049 (.049)</td>
</tr>
<tr>
<td>Interaction period 13</td>
<td>.019 (.039)</td>
</tr>
<tr>
<td>Interaction period 14</td>
<td>.045 (.041)</td>
</tr>
<tr>
<td>Interaction period 15</td>
<td>.043 (.040)</td>
</tr>
<tr>
<td>Interaction period 16</td>
<td>.065 (.044)</td>
</tr>
<tr>
<td>Interaction period 17</td>
<td>.024 (.039)</td>
</tr>
<tr>
<td>Interaction period 18</td>
<td>.026 (.038)</td>
</tr>
<tr>
<td>Interaction period 19</td>
<td>.015 (.036)</td>
</tr>
<tr>
<td>Interaction period 20</td>
<td>-.014 (.038)</td>
</tr>
<tr>
<td>Interaction period 21</td>
<td>-.029 (.039)</td>
</tr>
<tr>
<td>Interaction period 22</td>
<td>-.033 (.039)</td>
</tr>
<tr>
<td>Interaction period 23</td>
<td>-.019 (.037)</td>
</tr>
<tr>
<td>Interaction period 24</td>
<td>-.033 (.037)</td>
</tr>
<tr>
<td>Interaction period 25</td>
<td>-.035 (.043)</td>
</tr>
<tr>
<td>Interaction period 26</td>
<td>-</td>
</tr>
<tr>
<td>Ln price cap</td>
<td>.707** (.058)</td>
</tr>
<tr>
<td>Herfindahl-index/100</td>
<td>-.001 (.001)</td>
</tr>
<tr>
<td>Product dummies</td>
<td>Yes</td>
</tr>
<tr>
<td>Period dummies</td>
<td>Yes</td>
</tr>
<tr>
<td>Joint insignificance of interactions (Prob&gt;F)</td>
<td>.818</td>
</tr>
<tr>
<td>Number of observations</td>
<td>965</td>
</tr>
<tr>
<td>Number of products</td>
<td>47</td>
</tr>
<tr>
<td>R-squared</td>
<td>.53</td>
</tr>
</tbody>
</table>

*: significant at the 5% level. **: significant at the 1% level.
Table 4. Testing for pre- and post-reform differences in price trends for drugs in the comparison group. Fixed effect results with robust standard errors.

<table>
<thead>
<tr>
<th></th>
<th>(1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reform dummy</td>
<td>-.007 (.023)</td>
</tr>
<tr>
<td>Ln price cap</td>
<td>.778** (.019)</td>
</tr>
<tr>
<td>Herfindahl-index/100</td>
<td>.003 (.007)</td>
</tr>
<tr>
<td>Constant</td>
<td>.294** (.074)</td>
</tr>
<tr>
<td>Product dummies</td>
<td>Yes</td>
</tr>
<tr>
<td>Period dummies</td>
<td>Yes</td>
</tr>
<tr>
<td>Number of observations</td>
<td>1016</td>
</tr>
<tr>
<td>Number of products</td>
<td>24</td>
</tr>
<tr>
<td>R-squared</td>
<td>.69</td>
</tr>
</tbody>
</table>

**: significant at the 1% level.

Table 5. Price effects of reference pricing. Fixed effect results with robust standard errors.

<table>
<thead>
<tr>
<th></th>
<th>(1)</th>
<th>(2)</th>
<th>(3)</th>
<th>(4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Products subject to reference pricing</td>
<td>-.242** (.015)</td>
<td>-.189** (.019)</td>
<td>-.070** (.017)</td>
<td>-.076** (.020)</td>
</tr>
<tr>
<td>Branded products subject to reference pricing</td>
<td>-.110** (.026)</td>
<td>-.109** (.021)</td>
<td>-.107** (.021)</td>
<td></td>
</tr>
<tr>
<td>Ln price cap</td>
<td>.739** (.019)</td>
<td>.736** (.019)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic competitors* reference period</td>
<td>-0.063** (.017)</td>
<td>-0.060** (.016)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Branded therapeutic competitors* reference period</td>
<td>.060** (.016)</td>
<td>.060** (.016)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herfindahl-index/100</td>
<td>.002</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constant</td>
<td>1.738** (.019)</td>
<td>1.733** (.019)</td>
<td>.391** (.035)</td>
<td>.446** (.051)</td>
</tr>
<tr>
<td>Product dummies</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Period dummies</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Number of observations</td>
<td>2765</td>
<td>2765</td>
<td>2765</td>
<td>2765</td>
</tr>
<tr>
<td>Number of products</td>
<td>69</td>
<td>69</td>
<td>69</td>
<td>69</td>
</tr>
<tr>
<td>R-squared</td>
<td>.36</td>
<td>.37</td>
<td>.68</td>
<td>.69</td>
</tr>
</tbody>
</table>

**: significant at the 1% level.

So far we have not taken price cap regulation into account. From figure 1-4 we see that the brand-name prices follow the price cap quite closely. Since the development of the price cap differs among the three groups, it is important to control for changes in the price cap level. We find an estimated elasticity of around 0.74 (model 3), which clearly demonstrates the importance of this variable in the price setting behaviour of pharmaceutical companies. This finding confirms our first prediction from the theory section, namely that we expect a positive relationship between the price cap and the prices of brand-names and generics.
By comparing R-squared in model 2 and 3, we find that the price cap accounts for about 50 percent of the explained within-group variation in the dependent variable in our sample. More importantly, after controlling for this variable, we find that the estimated price effect of the reference price system is substantially lower. The price reduction for brand-names is about 18 percent, while generics face a price reduction of about 7 percent. This result is not surprising since we see from figure 2-4 that the drugs included in the reference price system face a reduction in the price cap, while the price cap for those not included is more stable.

Turning to a potential cross price effect, we find that prices on products that are therapeutic substitutes to those included in the reference price system have responded to the reform as well. A separation of the effect on brand-names and generics (model 4) reveals that it is merely the prices on therapeutic generics that respond to the reform, by price reduction of 6.4 percent, whereas the effect on branded therapeutic substitutes is statistically insignificant by an F-test and close to zero. A possible explanation is that the price cap is binding for the brand-names but not for the generics. This implies that we capture any price reductions on the generics, while for brand-names we observe only price reductions below the price cap. However, under free pricing, or less strict price regulation, it is likely that also the brand-names will reduce their prices as a response to the lower prices triggered by reference pricing.

Finally, in model 4, we control for the degree of competition by using the Herfindahl index. The estimated effect of this variable turns out to be statistically insignificant. However, due to a possible endogeneity problem, the result must be interpreted with some care. For example, the probability of generic entry in a market segment might be influenced by higher prices because of higher anticipated profit. This suggests a negative correlation between prices and the Herfindahl index, which indicates a downward bias in our estimates. One possible solution to this problem is to instrument for the variable, i.e., finding a variable that affects the market concentration but not directly affects the prices of existing products. However, since the estimated price effects of the reform are unaffected by the inclusion of the competition variable, and since it is hard to find good instruments, we choose not to do so in this study.

To summarize this section, we find that the introduction of reference pricing has led to an average price reduction of about 18 percent on brand names and 8 percent on generics. The reference pricing system also have a negative price effect on generics in the therapeutic substitute
group of about 6 percent. We have tested the robustness of these results by running a number of regressions, where we experiment with different model specifications, different comparison groups and the length of time periods. For example, we have estimated model 1 to 4 using a comparison group consisting of off-patent drugs facing generic competition only; we have tried to include different competition variables, like the number of generics and whether or not there is generic competition; we have also estimated the models using two and three month time periods. In all of these different regressions, we got results that did not differ substantially from those reported in table 5.26

7 Concluding remarks

We have analysed the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies, focusing on the relative performance of reference pricing and price cap regulation. A unique policy experiment from Norway, where a sub-sample of off-patent drugs was exposed to reference pricing, has been exploited to carefully identify the effects on pharmaceutical prices. Our analysis showed that the reference pricing system induced lower prices of both brand-names and generics exposed to the system. In addition, we identified a negative cross-price effect on therapeutic substitutes still under price cap regulation. Notably, our results are robust to different model specifications and choices of comparison groups, as discussed in the previous section.

We believe these results are interesting for several reasons. First, the results show that pharmaceutical firms’ respond to different regulatory regimes. In particular, reference pricing tends to trigger price competition and lead to lower prices than price cap regulation. This price response is not obvious considering the complicated structure of demand and supply in the pharmaceutical industry, including the presence of insurance and informational asymmetries. Some have also questioned whether reference pricing actually triggers competition (e.g., Danzon, 2001, Puig-Junoy, 2005). However, the pro-competitive effect seems very robust, as several recent studies, including ours, report lower prices and/or higher generic market shares due to reference pricing (Aronsson et al., 2001, Pavcnik, 2002, Bergman and Rudholm, 2003, Dalen et al., 2005).

26 The results from these regressions are available from the authors upon request.
Second, the policy experiment enables us to provide evidence, not only on generic competition, but, importantly, also on therapeutic competition. The negative cross-price effect on the therapeutic substitutes not exposed to the reference price system shows that there exists therapeutic competition in the market. The effect is, though, weaker than the direct price effect, which is consistent with Ellison et al. (1997) who show that generics are closer substitutes than brand-names with different chemical ingredients but similar therapeutic properties, a very intuitive result.

Third, the results provide some information in terms of policy implications. Reference pricing turns out to be more effective than price cap regulation in lowering drug prices. Assuming that total demand (not individual market shares) is relatively inelastic, this strongly indicates that reference pricing is superior in reducing medical expenditures. To indicate the economic significance of the reform, we can calculate the potential savings in medical expenditures. In 2002 the total sales value of the drugs included in the reference price system amounted to 474.4 mill NOK, with a brand-name market share of about 72 percent. Using our estimated price reductions of about 18 percent on brand-names and 8 percent of generics, we obtain cost saving of about 75 mill NOK. This is a conservative figure of two reasons. First, the reference price system is likely to trigger a shift in market shares from the brand-names to the generics (e.g., Aronsson et al., 2001). Second, when extending the reform to the whole generic market segment, the savings (in absolute terms) will be even higher.

However, the negative cross-price effect on therapeutic substitutes outside the system points at a potential detrimental aspect of reference pricing, namely that it may affect the patent rent and potentially stifle innovation. Clearly, this is not a great concern if only Norway introduced such a system, but reference pricing has become increasingly popular worldwide (e.g., Germany, Netherlands, New Zealand, British Columbia, etc). If an increasing number of large (and rich) countries implement reference pricing, or other price control mechanisms, it is likely that this would be harmful to pharmaceutical innovation, as pointed out by, for example, Danzon (2001) and Scherer (2001, 2004). A recent empirical study by Golec and Vernon (2006) demonstrates a negative impact of price constraints on pharmaceutical firms’ profitability, stock returns, and R&D spending. The relationship between price regulation and pharmaceutical innovation

27 A recent theoretical contribution to the relationship between reference pricing and pharmaceutical innovation
should also be highly relevant for the ongoing debate in the US after the inclusion of prescription drugs in the Medicare program.

Despite of its significant and intended effect on prices, the index price system was terminated by the end of December 2004. This decision was mainly based upon the results of a very early evaluation of the system that used data just until February 2004. Our analysis strongly indicates that the evaluation was carried out too early. Price reductions became substantial after some time, especially during 2004. The new regime, which was suggested by the pharmacy association, is new variant of generic reference pricing, where the reference price is a (step-wise) discount on the patent period brand-name price that becomes effective when generics have entered and been in the market for some time. How this new regime affects prices is hard to predict and is left for future research.

Finally, we would like to emphasis that our study does not perform a social welfare analysis of the different regulatory regimes. A complete welfare analysis would have to measure the effects of the reference price system on patients' health condition, the pharmaceutical firms' profits and innovation incentives, and, eventually, on the medical expenditures, potentially including the costs of public funds. Although our paper provides some partial information about profits and expenditures, through the price effects, a complete welfare analysis is outside the scope of the current paper and left for future research.

is provided by Bommier et al. (2006).
A Appendix

Figure A1. Average prices of brand-names and generics in the reference pricing group when excluding generics with entry in the sample period.

References


32


1999 Petra M. Geraats, Political Pressures and Monetary Mystique, May 2007


2001 Andreas Freytag and Friedrich Schneider, Monetary Commitment, Institutional Constraints and Inflation: Empirical Evidence for OECD Countries since the 1970s, May 2007


2004 Harrie A. A. Verbon, Migrating Football Players, Transfer Fees and Migration Controls, May 2007


2007 Andreas Schäfer and Thomas M. Steger, Macroeconomic Consequences of Distributional Conflicts, May 2007

2008 Mikael Priks, Judiciaries in Corrupt Societies, June 2007

2009 Steinar Holden and Fredrik Wulfsberg, Downward Nominal Wage Rigidity in the OECD, June 2007


2013 Axel Dreher and Martin Gassebner, Greasing the Wheels of Entrepreneurship? The Impact of Regulations and Corruption on Firm Entry, June 2007


2018 Hartmut Egger and Gabriel Felbermayr, Endogenous Skill Formation and the Source Country Effects of International Labor Market Integration, June 2007

2019 Bruno Frey, Overprotected Politicians, June 2007

2020 Jan Thomas Martini, Rainer Niemann and Dirk Simons, Transfer Pricing or Formula Apportionment? Tax-Induced Distortions of Multinationals’ Investment and Production Decisions, June 2007

2021 Andreas Buhn, Alexander Karmann and Friedrich Schneider, Size and Development of the Shadow Economy and of Do-it-yourself Activities in Germany, June 2007

2022 Michael Rauscher and Edward B. Barbier, Biodiversity and Geography, June 2007

2023 Gunther Schnabl, Exchange Rate Volatility and Growth in Emerging Europe and East Asia, June 2007

2024 Erkki Koskela and Ronnie Schob, Tax Progression under Collective Wage Bargaining and Individual Effort Determination, June 2007

2025 Jay Pil Choi and Marcel Thum, The Economics of Politically Connected Firms, June 2007

2026 Jukka Pirttila and Roope Uusitalo, Leaky Bucket in the Real World: Estimating Inequality Aversion Using Survey Data, June 2007

2027 Ruslan Lukach, Peter M. Kort and Joseph Plasmans, Strategic R&D with Knowledge Spillovers and Endogenous Time to Complete, June 2007
2028 Jarko Fidrmuc, Neil Foster and Johann Scharler, Labour Market Rigidities, Financial Integration and International Risk Sharing in the OECD, June 2007

2029 Bernardina Algieri and Thierry Bracke, Patterns of Current Account Adjustment – Insights from Past Experience, June 2007

2030 Robert Dur and Hein Roelfsema, Social Exchange and Common Agency in Organizations, June 2007

2031 Alexander Libman and Lars P. Feld, Strategic Tax Collection and Fiscal Decentralisation: The Case of Russia, June 2007

2032 Øystein Foros, Hans Jarle Kind and Greg Shaffer, Resale Price Maintenance and Restrictions on Dominant Firm and Industry-Wide Adoption, June 2007


2035 Nadia Fiorino and Roberto Ricciuti, Determinants of Direct Democracy, June 2007

2036 Burkhard Heer and Alfred Maussner, Inflation and Output Dynamics in a Model with Labor Market Search and Capital Accumulation, June 2007

2037 Konstantinos Angelopoulos, Jim Malley and Apostolis Philippopoulos, Public Education Expenditure, Growth and Welfare, June 2007

2038 Maarten Bosker, Steven Brakman, Harry Garretsen and Marc Schramm, Adding Geography to the New Economic Geography, June 2007


2040 Rosario Crinò, Service Offshoring and White-Collar Employment, July 2007


2042 Bart Cockx and Muriel Dejemeppe, Is the Notification of Monitoring a Threat to the Unemployed? A Regression Discontinuity Approach, July 2007

2043 Alfons J. Weichenrieder, Profit Shifting in the EU: Evidence from Germany, July 2007

2044 Annika Alexius and Bertil Holmlund, Monetary Policy and Swedish Unemployment Fluctuations, July 2007
2045 Axel Dreher, Jan-Egbert Sturm and Jakob de Haan, Does High Inflation Cause Central Bankers to Lose their Job? Evidence Based on a New Data Set, July 2007


2047 Alessandro Balestrino, It is a Theft but not a Crime, July 2007


2051 Gunther Schnabl and Christian Danne, A Role Model for China? Exchange Rate Flexibility and Monetary Policy in Japan, July 2007

2052 Joseph Plasman, Jorge Fornero and Tomasz Michalak, A Microfounded Sectoral Model for Open Economies, July 2007

2053 Vesa Kanniainen and Panu Poutvaara, Imperfect Transmission of Tacit Knowledge and other Barriers to Entrepreneurship, July 2007

2054 Marko Koethenbuerger, Federal Tax-Transfer Policy and Intergovernmental Pre-Commitment, July 2007

2055 Hendrik Jürges and Kerstin Schneider, What Can Go Wrong Will Go Wrong: Birthday Effects and Early Tracking in the German School System, July 2007

2056 Bahram Pesaran and M. Hashem Pesaran, Modelling Volatilities and Conditional Correlations in Futures Markets with a Multivariate t Distribution, July 2007


2059 Kurt R. Brekke, Astrid L. Grasdal and Tor Helge Holmås, Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?, July 2007